Lynparza Clinical Development Timeline
Chronicle of the development and US FDA review of AstraZeneca's olaparib in ovarian cancer (with and without a companion diagnostic test for germline BRCA mutations) and gBRCAm-breast cancer.
Chronicle of the development and US FDA review of AstraZeneca's olaparib in ovarian cancer (with and without a companion diagnostic test for germline BRCA mutations) and gBRCAm-breast cancer.